{
  "url": "https://www.law.cornell.edu/regulations/new-york/9-NYCRR-4043.12",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 9 ยง 4043.12 - Prohibited substances and methods",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 9 ยง 4043.12 - Prohibited substances and methods\n\nState Regulations\n(a) The substances and methods listed in the\nARCI prohibited list are prohibited, may not be used at any place or time and\nmay not be possessed on the premises of any racing or training facility under\nthe jurisdiction of the commission except as a restricted therapeutic use. ARCI\nprohibited list means the \"Prohibited List\" annexed to Model Rule ARCI-011-015\n\nVersion 7.0 (approved December 9, 2016) of the Association of Racing\n\nCommissioners International, Inc., 1510 Newtown Pike, Suite 210, Lexington, KY\n40511, which is hereby incorporated by reference. Such Uniform Rules of Racing\nare available for public inspection at the New York State Gaming Commission\nlocated at 354 Broadway, Schenectady, NY 12305 and at the Department of State, 99 Washington Avenue, Albany, NY 12231. (b) Restricted therapeutic use. A limited\nnumber of medications and methods listed in the ARCI Prohibited List shall be\nexempted when the administration occurs in compliance with the required\nconditions for restricted therapeutic use set forth in the table in this\nsubdivision, whose columns shall mean: (1)\n\nReport when sampled means the administration of the substance must be reported\nto the commission when the horse is next sampled, if the horse is sampled\nwithin 24 hours after the administration; (2)\n\nPre-File treatment plan means that if the\ncommission where the horse is located requires the filing of treatment plans, then a treatment plan for the substance must be filed by the time of\nadministration in a manner approved by such commission; (3)\n\nWritten approval from commission means\nthe commission has granted written approval of a written treatment plan before\nthe administration of the substance, including as may be required by the\ncolumn's footnotes; (4)\n\nEmergency\nuse (report) means the substance had to be administered due to an acute\nemergency involving the life or health of the horse, provided the emergency use\nis reported to the commission as soon as practicable after the treatment\noccurs; (5)\n\nPrescribed by\nveterinarian means the substance has been prescribed by an attending\nveterinarian in a manner consistent with the standards and procedures described\nin section\n4043.16\nof this Article and\nrecorded in a manner consistent with the requirements of section\n4012.4\nof this Article; (6)\n\nReport treatment means the treatment must\nbe reported to the commission by the trainer at the time of administration to\nprovide the commission with information for the veterinarian's list. The\ntrainer may delegate this responsibility to the treating veterinarian, who\nshall make the report when so designated; and\n(7)\n\nOther limitations means additional\nrequirements that apply, such as a substance may be used in only fillies or\nmares or a horse that is administered a substance shall be reported immediately\nto the commission and placed on the veterinarian's list for a specific minimum\nperiod of time. Required Conditions for Restricted Therapeutic\n\nUse\n\nProhibited substance\n\nReport when sampled\n\nPrefile treatment plan\n\nWritten approval from\ncommission\n\nEmergency use (report)\n\nPrescribed by veterinarian\n\nReport treatment\n\nOther limitations\nadrenocorticotropichormone\n(ACTH)\nx\nx\n-\nalbuterol\nx\n-\naltrenogest\nx\nfillies/ mares only\nautol ogous conditioned plasma\n(IRAP)\nx\nx\n-\nblood replacements\nx\nx\nx\n-\nboldenone\nx\nx\nx\n6-month vet list\nclenbuterol\nx\nx\nx\nx\n\nVet list\nchorionic gonadotropin\nx\nx-1\nx\nx\n60-day vet list\nfurosemide\nx\nx\n-\nluteinizing hor mone\nx\nx-1\nx\nx\n60-day vet list\nmesenchymal stem cells\nx\nx\nx\n-\nnandrolone\nx\nx\nx\n6-month vet list\nnucleic polymer transfers\nx\nx\nx\nx\n-\nplatelet rich plasma (PRP)\nx\nx\n-\nstanozolol\nx\nx\nx\n6-month vet list\nS0 (not FDA- approved)\nx-2\nx\n-\ntestosterone\nx\nx\nx\n6-month vet list\nthyroxine (T4)\nx\nx-3\nx\n-\ntrichlormex thiazide\nx\nx\n-\nother diuretics\nx\nx\nx\n-\nNotes: x-1: The approved treatment plan must show a specific treatment of a specific\nindividual horse for an undescended testicle condition. x-2: The approved treatment plan must show: (A)\nthe substance has a generally accepted\nveterinary use; (B)\nthe treatment\nprovides a significant health benefit for the horse; (C)\nthere is no reasonable therapeutic\nalternative; and\n(D)\nthe use of the\nsubstance is highly unlikely to produce any additional enhancement of\nperformance beyond what might be anticipated by a return to the horse's normal\nstate of health, not exceeding the level of performance of the horse prior to\nthe onset of the horse's medical condition. x-3: The approved treatment plan must show: (A)\nthe thyroxine is prescribed to a specific\nindividual horse for a specific period of time; (B)\nthe diagnosis and basis for prescribing\nsuch drug, the dosage, and the estimated last administration date; and\n(C)\nthat any container of such\ndrug on licensed premises shall be labeled with the foregoing information and\ncontain no more thyroxine than for the treatment of the specific individual\nhorse, as prescribed. (c) No person shall at any time administer\nany other doping agent to a horse except pursuant to a valid therapeutic, evidence-based treatment plan. (1)\n\nOther\ndoping agent means a substance that is not described in subdivision (a) of this\nsection or the ARCI Prohibited List, has a pharma-cologic potential to alter\nmaterially the performance of a horse, had no generally accepted medical use in\nthe horse when treated, and is: (i) capable\nat any time of causing an action or effect, or both, within one or more of the\nblood, cardiovascular, digestive, endocrine, immune, musculoskeletal, nervous, reproductive, respiratory, or urinary mammalian body systems; including without\nlimitation endocrine secretions and their synthetic counterparts, masking\nagents, oxygen carriers and agents that directly or indirectly affect or\nmanipulate gene expression; but\n(ii)\nnot a substance that is considered to\nhave no effect on the physiology of a horse except to improve nutrition or\ntreat or prevent infections or parasite infestations. (2)\n\nThe commission may publish advisory\nwarnings that certain substances or administrations may constitute a violation\nof this section. (3)\n\nTherapeutic, evidence-based treatment plan means a planned course of treatment written and\nprescribed by an attending veterinarian before the horse is treated that: (i) describes the medical need of the horse\nfor the treatment, the evidence-based scientific or clinical justification for\nusing the doping agent and a determination that recognized therapeutic\nalternates do not exist; and\n(ii)\ncomplies with section\n4043.16\nof this Part, meets the\nstandards of veterinary practice in the jurisdiction and is developed in good\nfaith to treat a medical need of the horse. (4)\n\nSuch plans shall not authorize the\npossession of a doping agent on the premises of a racing or training facility\nunder the jurisdiction of the commission. (5)\n\nIf the other doping agent is a protein-\nor peptide-based agent or drug that may produce analgesia or enhance the\nperformance of a horse beyond such horse's natural ability, then the\nadministration of such substance to such horse and the possession of such\nsubstance on the premises of a licensed racetrack also shall be\n(i) limited to a time, place and manner\nspecifically permitted in writing by the commission before the administration\nof such substance; (ii)\nfor a\nrecognized therapeutic use; and\n(iii)\nsubject to such appropriate limitations\nas the commission may place on the return of the horse to running\nraces. (d) Consistency with other restrictions. (1)\n\nThe\nprohibited doping agents, substances and methods described in this section are\nprohibited regardless of any other sections, including 4043.2 and 4043.3, of\nthis Part. (2)\n\nThe use of a\nprohibited doping agent, substance or method under conditions permitted by this\nsection must also comply with other applicable rules of the commission, including, without limitation, sections\n4043.2, 4043.3, 4043.6, 4043.15\nand\n4043.16\nof this Part. (e) Penalties. (1)\nA horse found to be in violation of this\nsection shall be ineligible to participate in racing until it is certain that\nthe horse is no longer affected by the prohibited substance or method and for\nnot less than 180 days, after which the horse must qualify in a workout\nsatisfactory to the stewards and test negative for prohibited or impermissible\ndrugs or other substances. The minimum fixed period of ineligibility for a\nhorse in violation of this section shall be reduced from 180 to 30 days if the\ntrainer had never violated this rule or similar rules in other jurisdictions\nand had, for any violations of Part 4043 or similar rules in other\njurisdictions, fewer than 180 days in lifetime suspensions or revocations and\nfewer than two suspensions or revocations of 15 days or more in the preceding\n24 months. (2)\nA person who is\nfound responsible for a prohibited substance or method in violation of this\nsection shall, in the absence of extraordinary mitigating circumstances, incur\na minimum penalty of license revocation in addition to any other penalties\nauthorized in this Article. (f) A buyer who was not aware that a horse is\nor may be determined ineligible under this section may void the purchase, provided that the buyer does so within 10 days after receiving actual or\nconstructive notice of the horse's ineligibility. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 9\nยง\n4043.12\n\nAmended\n\nNew\n\nYork State Register August 1, 2018/Volume XL, Issue 31, eff. 8/1/2018\n\nAmended\n\nNew\n\nYork State Register June 2, 2021/Volume XLIII, Issue 22, eff. 6/2/2021\n\nAmended\n\nNew\n\nYork State Register July 10, 2024/Volume XLVI, Issue 28, eff. 7/10/2024\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. No prior version found.",
  "url_type": "regulation",
  "source_index": 3333
}